Neuropathix Revenue and Competitors

Doylestown, PA

Location

$4.5M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Neuropathix's estimated annual revenue is currently $301.5k per year.(i)
  • Neuropathix's estimated revenue per employee is $100,500
  • Neuropathix's total funding is $4.5M.

Employee Data

  • Neuropathix has 3 Employees.(i)
  • Neuropathix grew their employee count by 0% last year.

Neuropathix's People

NameTitleEmail/Phone
1
Chief ChemistReveal Email/Phone
2
Chief Communications OfficerReveal Email/Phone
3
Chief Scientific OfficerReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M2156%N/AN/A
#2
$81.8M40710%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M2231%N/AN/A
#6
$13.1M655%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M86-5%N/AN/A
#9
$67.9M33823%N/AN/A
#10
$14.9M747%N/AN/A
Add Company

What Is Neuropathix?

Neuropathix is a biopharmaceutical company focused on the research and development of a pipeline of next generation socially responsible pain management therapeutics to treat patients with significant unmet medical needs.

keywords:N/A

$4.5M

Total Funding

3

Number of Employees

$301.5k

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Neuropathix News

2022-04-06 - 2022-04-13 | OTCQB:NPTX | Press Release | Neuropathix Inc

Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019. NPTX | 10 days ago.

2022-04-06 - Neuropathix, Inc. Highlights Positive Preclinical Study Results ...

Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019. By. ACCESSWIRE.

2022-03-30 - Medical Marijuana, Inc. Provides Update on its Pharmaceutical Initiatives

Neuropathix (OTCQB: NPTX), a major investment of Medical Marijuana, Inc. and a socially responsible pain management life sciences company,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.2M3-40%N/A
#2
$0.4M50%N/A
#3
$0.4M5-37%N/A
#4
$0.4M50%N/A
#5
$0.6M5-17%N/A